Akshay Motilal Baheti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akshay Motilal Baheti has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Amol Ambadas Tagalpallewar
School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India
5 shared publications - Anil Tukaram Pawar
School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India
4 shared publications Anil T. Pawar
Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune-411038, Maharashtra, India
3 shared publicationsAmeya Joshi
School of Pharmacy, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, INDIA
2 shared publicationsAmol A. Tagalpallewar
Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India
2 shared publicationsAmol Tagalpallewar
School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, Maharashtra, India
2 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Myristica malabarica as a Multitarget Therapeutic Candidate for Breast Cancer and Type 2 Diabetes Mellitus: An Integrated Network Pharmacology and In-Vitro Investigation
This study elucidates the therapeutic potential of Myristica malabarica Lam. and its primary bioactive constituent, Malabaricone C, for breast cancer and type 2 diabetes mellitus (T2DM) through an integrated in-silico and in-vitro approach. Network pharmacology, utilizing GeneCards, DrugBank, STRING, and Cytoscape, identified 10 core targets (e.g., EGFR, PPARγ) and mapped them to apoptosis and insulin signaling pathways via KEGG analysis. Molecular docking with AutoDock Tools demonstrated Malabaricone C’s high-affinity interactions, yielding binding energies of −12.3 kcal/mol for EGFR (PDB ID: 2XKN), −9.8 kcal/mol for PPARγ (PDB ID: 1U5D), −8.7 kcal/mol for GLP-1 receptor (PDB ID: 5VSF), and −9.1 kcal/mol for HER2 (PDB ID: 1N8Z), surpassing standard reference drugs 5-Fluorouracil (−3.8 to −8.3 kcal/mol) and Glibenclamide (−4.2 to −5.6 kcal/mol). In-vitro assays were performed for crude chloroform extract, hexane extract, and Malabaricone C confirmed via HR-LCMS in MCF-7 breast cancer cells and MIN6 β-cells. Crude extracts exhibited moderate cytotoxicity (IC50: 61.29–73.03 µg/mL vs. 6 µg/mL for 5-Fluorouracil) and insulinotropic activity (96–100.8 µU/mL vs. 150.78 µU/mL for Glibenclamide at 100 µg/mL), which was attributed to phytochemical interference within their complex matrix. In contrast, Malabaricone C’s in-silico efficacy, validated by its reported induction of apoptosis in MCF-7 cells and PPARγ/AMPK activation for T2DM, underscores its superior polypharmacological potential. These findings highlight the limitations of crude extracts and advocate for Malabaricone C’s isolation and further in-vitro and in-vivo validation to advance its clinical translation.
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMyristica malabarica as a Multitarget Therapeutic Candidate for Breast Cancer and Type 2 Diabetes Mellitus: An Integrated Network Pharmacology and In-Vitro Investigation
This study elucidates the therapeutic potential of Myristica malabarica Lam. and its primary bioactive constituent, Malabaricone C, for breast cancer and type 2 diabetes mellitus (T2DM) through an integrated in-silico and in-vitro approach. Network pharmacology, utilizing GeneCards, DrugBank, STRING, and Cytoscape, identified 10 core targets (e.g., EGFR, PPARγ) and mapped them to apoptosis and insulin signaling pathways via KEGG analysis. Molecular docking with AutoDock Tools demonstrated Malabaricone C’s high-affinity interactions, yielding binding energies of −12.3 kcal/mol for EGFR (PDB ID: 2XKN), −9.8 kcal/mol for PPARγ (PDB ID: 1U5D), −8.7 kcal/mol for GLP-1 receptor (PDB ID: 5VSF), and −9.1 kcal/mol for HER2 (PDB ID: 1N8Z), surpassing standard reference drugs 5-Fluorouracil (−3.8 to −8.3 kcal/mol) and Glibenclamide (−4.2 to −5.6 kcal/mol). In-vitro assays were performed for crude chloroform extract, hexane extract, and Malabaricone C confirmed via HR-LCMS in MCF-7 breast cancer cells and MIN6 β-cells. Crude extracts exhibited moderate cytotoxicity (IC50: 61.29–73.03 µg/mL vs. 6 µg/mL for 5-Fluorouracil) and insulinotropic activity (96–100.8 µU/mL vs. 150.78 µU/mL for Glibenclamide at 100 µg/mL), which was attributed to phytochemical interference within their complex matrix. In contrast, Malabaricone C’s in-silico efficacy, validated by its reported induction of apoptosis in MCF-7 cells and PPARγ/AMPK activation for T2DM, underscores its superior polypharmacological potential. These findings highlight the limitations of crude extracts and advocate for Malabaricone C’s isolation and further in-vitro and in-vivo validation to advance its clinical translation.
- Open Access
- 20 November 2025
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 16 (6) , 101267
Anti-inflammatory effects of Glycyrrhiza glabra homeopathic formulations in a rat model of lipopolysaccharide-induced inflammation
- 20 November 2025
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 16 (6) , 101267
Open AccessAnti-inflammatory effects of Glycyrrhiza glabra homeopathic formulations in a rat model of lipopolysaccharide-induced inflammation
- 16 July 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353 (Pt A) , 120301
Network pharmacology, in-silico and in-vivo studies for analgesic and antipyretic activities of Haplanthodes tentaculata (L) leaves
- 16 July 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353 (Pt A) , 120301
Network pharmacology, in-silico and in-vivo studies for analgesic and antipyretic activities of Haplanthodes tentaculata (L) leaves
- 12 June 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (6) , 2910-2918
Harnessing the Power of Flavonoids: A Natural Remedy for Urolithiasis
Urolithiasis ranks as the third most prevalent kidney disease, affecting 12-15% of the global population. It has a recurrence rate of 70-81% in males and 47-60% in females. Kidney stone disorder is a complex condition that progresses through several stages, including supersaturation, nucleation, growth, aggregation, and retention within the kidneys. This condition can lead to significant medical issues, such as infections, urinary tract obstruction, and severe pain. Most kidney stones primarily consist of calcium oxalate. While treatments such as surgery, ureteroscopy, percutaneous nephrostolithotomy and open or laparoscopic stone removal are available, they are often unpleasant and costly. Herbal remedies continue to be employed for the treatment and prevention of kidney stones. Recent studies have demonstrated that plant flavonoids exhibit significant anti-inflammatory, antioxidant, diuretic, antibacterial, and other beneficial effects against kidney stone formation, both in vitro and in vivo. Therefore, flavonoids or plant extracts rich in flavonoids associated with anti-urolithiasis activity have been evaluated. This article emphasizes the use of plants as a remedy for kidney stones. It reviews the types of kidney stones, the pathophysiology of stone formation, the role of natural diet in kidney stone development, and the role of flavonoids in managing urolithiasis.
- 12 June 2025
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 18 (6) , 2910-2918
Harnessing the Power of Flavonoids: A Natural Remedy for Urolithiasis
Urolithiasis ranks as the third most prevalent kidney disease, affecting 12-15% of the global population. It has a recurrence rate of 70-81% in males and 47-60% in females. Kidney stone disorder is a complex condition that progresses through several stages, including supersaturation, nucleation, growth, aggregation, and retention within the kidneys. This condition can lead to significant medical issues, such as infections, urinary tract obstruction, and severe pain. Most kidney stones primarily consist of calcium oxalate. While treatments such as surgery, ureteroscopy, percutaneous nephrostolithotomy and open or laparoscopic stone removal are available, they are often unpleasant and costly. Herbal remedies continue to be employed for the treatment and prevention of kidney stones. Recent studies have demonstrated that plant flavonoids exhibit significant anti-inflammatory, antioxidant, diuretic, antibacterial, and other beneficial effects against kidney stone formation, both in vitro and in vivo. Therefore, flavonoids or plant extracts rich in flavonoids associated with anti-urolithiasis activity have been evaluated. This article emphasizes the use of plants as a remedy for kidney stones. It reviews the types of kidney stones, the pathophysiology of stone formation, the role of natural diet in kidney stone development, and the role of flavonoids in managing urolithiasis.
- Open Access
- 23 May 2025
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 16 (3) , 101105
Eighteen months of non-union of an upper third tibial fracture treated with Ayurvedic herbal medicines and Panchakarma: A case report
- 23 May 2025
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 16 (3) , 101105
Open AccessEighteen months of non-union of an upper third tibial fracture treated with Ayurvedic herbal medicines and Panchakarma: A case report
- Open Access
- 18 July 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (4) , 100976
Five years of disease-free survival in a case of recurrent, post-op, grade 3, stage 2, Malignant Spindle Cell Melanoma treated with Ayurvedic medicines: A case report
- 18 July 2024
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 15 (4) , 100976
Open AccessFive years of disease-free survival in a case of recurrent, post-op, grade 3, stage 2, Malignant Spindle Cell Melanoma treated with Ayurvedic medicines: A case report
- Open Access
- 22 January 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (2)
Integrating network pharmacology and in silico analysis deciphers Withaferin-A’s anti-breast cancer potential via hedgehog pathway and target network interplay
This study examines the remarkable effectiveness of Withaferin-A (WA), a withanolide obtained from Withania somnifera (Ashwagandha), in encountering the mortiferous breast malignancy, a global peril. The predominant objective is to investigate WA’s intrinsic target proteins and hedgehog (Hh) pathway proteins in breast cancer targeting through the application of in silico computational techniques and network pharmacology predictions. The databases and webtools like Swiss target prediction, GeneCards, DisGeNet and Online Mendelian Inheritance in Man were exploited to identify the common target proteins. The culmination of the WA network and protein–protein interaction network were devised using Stitch and String web tools, through which the drug–target network of 30 common proteins was constructed employing Cytoscape-version 3.9. Enrichment analysis was performed by incorporating Gprofiler, Metascape and Cytoscape plugins. David compounded the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes, and enrichment was computed through bioinformatics tools. The 20 pivotal proteins were docked harnessing Glide, Schrodinger Suite 2023-2. The investigation was governed by docking scores and affinity. The shared target proteins underscored the precise Hh and WA network roles with the affirmation enrichment P-value of P < 0.01). Further, the ADMET and drug-likeness assessments assisted the claim. Robust interactions were noticed with docking studies, authenticated through molecular dynamics, molecular mechanics generalized born surface area scores and bonds. The computational investigation emphasized WA’s credible anti-breast activity, specifically with Hh proteins, implying stem-cell-level checkpoint restraints. Rigorous testament is imperative through in vitro and in vivo studies.
- 22 January 2024
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (2)
Open AccessIntegrating network pharmacology and in silico analysis deciphers Withaferin-A’s anti-breast cancer potential via hedgehog pathway and target network interplay
This study examines the remarkable effectiveness of Withaferin-A (WA), a withanolide obtained from Withania somnifera (Ashwagandha), in encountering the mortiferous breast malignancy, a global peril. The predominant objective is to investigate WA’s intrinsic target proteins and hedgehog (Hh) pathway proteins in breast cancer targeting through the application of in silico computational techniques and network pharmacology predictions. The databases and webtools like Swiss target prediction, GeneCards, DisGeNet and Online Mendelian Inheritance in Man were exploited to identify the common target proteins. The culmination of the WA network and protein–protein interaction network were devised using Stitch and String web tools, through which the drug–target network of 30 common proteins was constructed employing Cytoscape-version 3.9. Enrichment analysis was performed by incorporating Gprofiler, Metascape and Cytoscape plugins. David compounded the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes, and enrichment was computed through bioinformatics tools. The 20 pivotal proteins were docked harnessing Glide, Schrodinger Suite 2023-2. The investigation was governed by docking scores and affinity. The shared target proteins underscored the precise Hh and WA network roles with the affirmation enrichment P-value of P < 0.01). Further, the ADMET and drug-likeness assessments assisted the claim. Robust interactions were noticed with docking studies, authenticated through molecular dynamics, molecular mechanics generalized born surface area scores and bonds. The computational investigation emphasized WA’s credible anti-breast activity, specifically with Hh proteins, implying stem-cell-level checkpoint restraints. Rigorous testament is imperative through in vitro and in vivo studies.
- 8 June 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (8) , 4263-4282
Pharmacoinformatics approach for the screening of Kovidra (Bauhinia variegata) phytoconstituents against tumor suppressor protein in triple negative breast cancer
Globally, 2.3 million women were diagnosed with breast cancer, with 6,85000 mortalities in year 2021; making it the world's most prevalent cancer. This growing global burden necessitates a new treatment option, and plant-based medicines offers a promising alternative to conventional cancer treatment. In this work, screening of phytoconstituents of an indigenous therapeutic plant, Bauhinia variegata carried out for potential regulator of tumor suppressor protein p53. Here, an in-silico analysis was employed to develop more effective, pharmaceutically potent small drug-like compounds that target tumor suppressor protein p53. The methanol and aqueous powdered extracts of Bauhinia variegata were prepared and phytochemically evaluated along with antioxidant property evaluation. The LC50 of methanol (325.33 µg/ml) and aqueous extract (361.15 µg/ml) showed their cytotoxic characteristics. Further, GCMS analysis of both the extracts reveals total 57 secondary metabolites. Among these, four lead compounds; compound 1, compound 2, compound 3 and compound 4 were found to have the highest binding ability (-8.15 to -5.40 kcal/mol) with p53. MD simulation and binding free energy validates these findings with highest binding free energy (-67.09 ± 4.87 kcal/mol) towards p53 by the lead phytocompound 2. Selected compounds exhibit excellent pharmacokinetic features and drug-like characteristics. The acute toxicity (LD50) values of the lead phytocompounds ranges from 670 mg/kg to 3100 mg/kg, with toxicity classes of IV and V. As a result, these druggable phytochemicals could serve as potential lead applicants for triple negative breast cancer treatment. However, more in vitro and in vivo research is planned to produce future breast cancer medicine. HIGHLIGHTSScreening of phytoconstituents of an indigenous therapeutic plant, Bauhinia variegata, for potential regulator of tumor suppressor protein p53.The LC50 of methanol (325.33µg/ml) and aqueous extract (361.15µg/ml) showed their cytotoxic characteristics.GCMS analysis of both the extracts reveals total 57 secondary metabolites. Among these, four lead compounds were found to have the highest binding affinity (-8.153 to -5.401 kcal/mol) with tumor suppressor protein p53.MD simulation along with the Prime MM/GBSA binding free energy validates this discovery with highest binding free energy (-67.09 ± 4.87 kcal/mol) towards p53 by the lead compound 2.The acute toxicity (LD50) values of the lead phytocompounds ranges from 670 mg/kg to 3100 mg/kg, with toxicity classes of IV and V.As a result, these druggable phytochemicals could serve as potential lead applicants for triple negative breast cancer treatment.Communicated by Ramaswamy H. Sarma.
- 8 June 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 42 (8) , 4263-4282
Pharmacoinformatics approach for the screening of Kovidra (Bauhinia variegata) phytoconstituents against tumor suppressor protein in triple negative breast cancer
Globally, 2.3 million women were diagnosed with breast cancer, with 6,85000 mortalities in year 2021; making it the world's most prevalent cancer. This growing global burden necessitates a new treatment option, and plant-based medicines offers a promising alternative to conventional cancer treatment. In this work, screening of phytoconstituents of an indigenous therapeutic plant, Bauhinia variegata carried out for potential regulator of tumor suppressor protein p53. Here, an in-silico analysis was employed to develop more effective, pharmaceutically potent small drug-like compounds that target tumor suppressor protein p53. The methanol and aqueous powdered extracts of Bauhinia variegata were prepared and phytochemically evaluated along with antioxidant property evaluation. The LC50 of methanol (325.33 µg/ml) and aqueous extract (361.15 µg/ml) showed their cytotoxic characteristics. Further, GCMS analysis of both the extracts reveals total 57 secondary metabolites. Among these, four lead compounds; compound 1, compound 2, compound 3 and compound 4 were found to have the highest binding ability (-8.15 to -5.40 kcal/mol) with p53. MD simulation and binding free energy validates these findings with highest binding free energy (-67.09 ± 4.87 kcal/mol) towards p53 by the lead phytocompound 2. Selected compounds exhibit excellent pharmacokinetic features and drug-like characteristics. The acute toxicity (LD50) values of the lead phytocompounds ranges from 670 mg/kg to 3100 mg/kg, with toxicity classes of IV and V. As a result, these druggable phytochemicals could serve as potential lead applicants for triple negative breast cancer treatment. However, more in vitro and in vivo research is planned to produce future breast cancer medicine. HIGHLIGHTSScreening of phytoconstituents of an indigenous therapeutic plant, Bauhinia variegata, for potential regulator of tumor suppressor protein p53.The LC50 of methanol (325.33µg/ml) and aqueous extract (361.15µg/ml) showed their cytotoxic characteristics.GCMS analysis of both the extracts reveals total 57 secondary metabolites. Among these, four lead compounds were found to have the highest binding affinity (-8.153 to -5.401 kcal/mol) with tumor suppressor protein p53.MD simulation along with the Prime MM/GBSA binding free energy validates this discovery with highest binding free energy (-67.09 ± 4.87 kcal/mol) towards p53 by the lead compound 2.The acute toxicity (LD50) values of the lead phytocompounds ranges from 670 mg/kg to 3100 mg/kg, with toxicity classes of IV and V.As a result, these druggable phytochemicals could serve as potential lead applicants for triple negative breast cancer treatment.Communicated by Ramaswamy H. Sarma.